Table 5.
VF-s exhibiting significant prevalence differences according to geographical origin among 423 ESBL producing E. coli strains.
| VF | Gene | Number of isolates (% of total) | P | |||
|---|---|---|---|---|---|---|
| Estoniaa
(n = 149) |
Latviab
(n = 112) |
Lithuaniac
(n = 35) |
Russiad
(n = 127) |
|||
| Adhesins | papAH | 14 (9) | 8 (7) | 5 (14) | 38 (30) | ≤0.001ad,bd |
| papEF | 13 (9) | 10 (9) | 3 (9) | 41 (32) | ≤0.001ad,cd; 0.005bd |
|
| papC | 20 (13) | 29 (26) | 6 (17) | 46 (36) | ≤0.05ab,cd; 0.001ad |
|
| papGII | 3 (2) | 24 (21) | 4 (11) | 40 (31) | ≤0.02ac,cd; ≤0.001ab,ad |
|
| sfa/focDE | 28 (19) | 9 (8) | 5 (14) | 3 (2) | ≤0.02ab,cd; 0.001ad |
|
| focG | 2 (1) | 1 (1) | 2 (6) | 0 (0) | 0.05cd | |
|
| ||||||
| Toxins | hlyA | 24 (16) | 12 (11) | 4 (11) | 28 (22) | 0.02bd |
| cvaC | 18 (12) | 13 (12) | 10 (29) | 8 (6) | ≤0.03ac,bc; ≤0.001cd |
|
|
| ||||||
| Capsule | kpsMTII | 78 (52) | 77 (69) | 9 (26) | 40 (31) | ≤0.008ab,ac,ad; ≤0.001bc,bd |
| kpsMTIII | 81 (54) | 80 (71) | 27 (77) | 63 (50) | 0.01ac; ≤0.007ab,bd,cd |
|
| rfc | 0 (0) | 0 (0) | 1 (3) | 4 (3) | 0.04ad | |
|
| ||||||
| Siderophores | fyuA | 125 (84) | 90 (80) | 25 (71) | 112 (88) | 0.03cd |
| iutA | 106 (71) | 101 (90) | 28 (74) | 108 (85) | 0.02bc; ≤0.001ab,ad |
|
|
| ||||||
| Invasin | ibeA | 27 (18) | 3 (3) | 4 (11) | 3 (2) | 0.04cd; ≤0.001ab,ad |
|
| ||||||
| Serum resistance | traT | 110 (74) | 110 (98) | 33 (94) | 111 (87) | ≤0.007ac,ad,bd
0.001ab |
a,b,c,dIndicate strains isolated from different countries.